Adverum Biotechnologies, Inc.

    Adverum Biotechnologies, Inc.

    NNASDAQ:ADVM
    4.36
    USD
    0.00
    (0.00%)
    2012 Y
    2013 Y
    2014 Y
    2015 Y
    2016 Y
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    TTM
    Revenue per Share
    - -
    - -
    0.25
    0.9
    0.4
    0.42
    0.26
    0.04
    - -
    0.77
    - -
    0.36
    0.05
    - -
    Basic EPS, GAAP
    -0.87
    -2.54
    -12.58
    -18.35
    -31.38
    -12.86
    -11.83
    -10.06
    -13.8
    -14.85
    -15.57
    -12.11
    -6.62
    -9.47
    Free Cash Flow per Basic Share
    -0.61
    -1.09
    -2.9
    -14.82
    -11.25
    -10.64
    -8.92
    -10.67
    -10.7
    -12.54
    -12.08
    -9.1
    -4.69
    -6.41
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    -1.73
    -4.27
    -16.13
    -32.55
    -54.6
    -58.19
    -52.23
    -60.06
    -59.02
    -66.1
    -80.87
    -92.84
    -53.94
    -56.1
    Tangible Book Value per Share
    -1.67
    -3.95
    65.7
    97.68
    58.1
    41
    32.78
    27.29
    51.01
    32.25
    18.29
    6.67
    3.57
    -2.58
    Basic Weighted Avg Shares
    2
    2
    2
    3
    4
    4
    6
    6
    9
    10
    10
    10
    20
    22
    Sales/Revenue/Turnover
    - -
    - -
    1
    2
    1
    2
    2
    - -
    - -
    8
    - -
    4
    1
    - -
    Operating Margin (%)
    - -
    - -
    -4,266.08
    -1,951.27
    -3,750.52
    -3,182.64
    -4,533.56
    -27,418
    - -
    -1,948.29
    - -
    -3,581.72
    -13,915.9
    - -
    Depreciation Expense
    - -
    - -
    - -
    1
    2
    2
    2
    2
    4
    5
    7
    6
    4
    2
    Net Income, GAAP
    -2
    -5
    -25
    -47
    -114
    -56
    -73
    -64
    -118
    -146
    -155
    -122
    -131
    -204
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    - -
    - -
    -4,441.26
    -2,046.27
    -7,817.66
    -3,036.61
    -4,505.4
    -25,794.4
    - -
    -1,940.53
    - -
    -3,392.11
    -13,092.7
    - -
    Working Capital
    - -
    - -
    155
    254
    215
    183
    198
    156
    414
    296
    158
    83
    108
    -16
    LT Debt
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    28
    26
    101
    94
    69
    86
    83
    Total Equity
    -1
    - -
    149
    253
    216
    184
    201
    175
    434
    316
    182
    67
    71
    -56
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Mar'25
    Jun'25
    Sep'25
    ST Debt
    7
    7
    6
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    86
    85
    83
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    21
    21
    22
    Market Capitalization
    91
    45
    98

    Working Capital

    USD

    •

    in mil. unless spec.
    Mar'25
    Jun'25
    Sep'25
    Total Current Assets
    89
    48
    29
    Cash, Cash Equivalents & STI
    83
    44
    26
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    25
    31
    45
    Payables & Accruals
    12
    16
    28
    ST Debt
    7
    7
    6
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    5.67%
    4.14%
    5.19%
    Free Cash Flow
    58.8%
    8.67%
    1.24%
    Net Income, GAAP
    29.25%
    19.7%
    7.22%
    Sales/Revenue/Turnover
    - -
    - -
    -72.22%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    4
    - -
    - -
    - -
    4
    2024
    - -
    - -
    1
    - -
    1
    2025
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -2.9
    -3.13
    -3.26
    - -
    -12.11
    2024
    -1.65
    -1.46
    -1.55
    -2.9
    -6.62
    2025
    -2.25
    -2.34
    -2.03
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • defenseworld.net

      Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives $10.50 Consensus Target Price from Analysts

    • gurufocus.com

      First Look: Fed Cut Looms; SpaceX IPO; J&J Myeloma Data; Google Probe

    • prnewswire.com

      Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition

    • globenewswire.com

      Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly

    • prnewswire.com

      Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights

    • defenseworld.net

      Adverum Biotechnologies (ADVM) Projected to Post Quarterly Earnings on Monday

    • businesswire.com

      ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. Is Fair to Shareholders

    • businesswire.com

      Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM

    • prnewswire.com

      $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Adverum Biotechnologies, Inc. (NASDAQ: ADVM)

    • prnewswire.com

      Shareholder Alert: The Ademi Firm investigates whether Adverum Biotechnologies, Inc. is obtaining a Fair Price for its Public Shareholders

    • reuters.com

      Eli Lilly to buy gene therapy developer Adverum in about $262 million deal

    • globenewswire.com

      ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. is Fair to Shareholders

    • prnewswire.com

      Lilly to Acquire Adverum Biotechnologies

    • globenewswire.com

      Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration

    • globenewswire.com

      Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    • globenewswire.com

      Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights

    • globenewswire.com

      Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

    • globenewswire.com

      Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    • globenewswire.com

      Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights

    • accessnewswire.com

      INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM